Canada markets open in 6 hours 49 minutes

Aridis Pharmaceuticals, Inc. (ARDS)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0717-0.0017 (-2.36%)
At close: 03:12PM EDT
Currency in USD

Valuation Measures4

Market Cap (intraday) 3.20M
Enterprise Value 8.00M
Trailing P/E 2.83
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/Sales (ttm)0.15
Price/Book (mrq)5.40
Enterprise Value/Revenue 0.41
Enterprise Value/EBITDA -9.06

Trading Information

Stock Price History

Beta (5Y Monthly) 1.03
52-Week Change 3-69.54%
S&P500 52-Week Change 323.42%
52 Week High 30.5395
52 Week Low 30.0500
50-Day Moving Average 30.0745
200-Day Moving Average 30.1016

Share Statistics

Avg Vol (3 month) 398.06k
Avg Vol (10 day) 370.27k
Shares Outstanding 544.57M
Implied Shares Outstanding 645.66M
Float 837.24M
% Held by Insiders 114.84%
% Held by Institutions 110.38%
Shares Short (Jun 30, 2023) 42M
Short Ratio (Jun 30, 2023) 40.22
Short % of Float (Jun 30, 2023) 46.80%
Short % of Shares Outstanding (Jun 30, 2023) 45.55%
Shares Short (prior month May 31, 2023) 4439.68k

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 30.00
Trailing Annual Dividend Yield 30.00%
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2022
Most Recent Quarter (mrq)Sept 30, 2023


Profit Margin -5.11%
Operating Margin (ttm)-208.39%

Management Effectiveness

Return on Assets (ttm)-4.40%
Return on Equity (ttm)N/A

Income Statement

Revenue (ttm)22.36M
Revenue Per Share (ttm)0.69
Quarterly Revenue Growth (yoy)4.50%
Gross Profit (ttm)N/A
EBITDA -347k
Net Income Avi to Common (ttm)-1.14M
Diluted EPS (ttm)-0.1600
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)35k
Total Cash Per Share (mrq)0
Total Debt (mrq)4.84M
Total Debt/Equity (mrq)N/A
Current Ratio (mrq)0.23
Book Value Per Share (mrq)-0.26

Cash Flow Statement

Operating Cash Flow (ttm)-17.89M
Levered Free Cash Flow (ttm)-16.39M